We are live on
!
Find out more
CPX
Canaan Partners XI Portfolio holdings
AUM
$127M
1-Year Est. Return
217.49%
This Fund
S&P 500
This Quarter
Est. Return
-21.02%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$77.3M
AUM Growth
-$40.8M
(-35%)
Cap. Flow
-$4.4M
Cap. Flow
% of AUM
-5.69%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tyra Biosciences
TYRA
|
+$4.18M |
| 2 |
Rallybio
RLYB
|
+$223K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.28% |
| 2 | Technology | 22.72% |
Similar funds
CF
MF
SAP
S
PIP
VDC
SIM
PC
Canaan Partners XI's Q4 2024 Portfolio in Review
As of Q4 2024, Canaan Partners XI held 3 positions worth $77.3M, down 35% from $118M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Canaan Partners XI withdrew a net $4.4M in Q4 2024, reducing 2 holdings. Its largest reduction was Tyra Biosciences, cutting an estimated $4.18M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 90% a quarter earlier, followed by Technology.
- Canaan Partners XI's biggest Q4 2024 reduction was Tyra Biosciences, cutting an estimated $4.18M.
- Canaan Partners XI's ten largest holdings make up 100% of its $77.3M portfolio in Q4 2024.
- Canaan Partners XI opened 0 new positions and closed 0 in Q4 2024.
- Canaan Partners XI's portfolio value fell 35% quarter-over-quarter to $77.3M.
Based on Canaan Partners XI's 13F filing for Q4 2024, filed 21 Jan 2025.